Your browser doesn't support javascript.
loading
GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.
Lindberg, Olle R; McKinney, Andrew; Engler, Jane R; Koshkakaryan, Gayane; Gong, Henry; Robinson, Aaron E; Ewald, Andrew J; Huillard, Emmanuelle; David James, C; Molinaro, Annette M; Shieh, Joseph T; Phillips, Joanna J.
Afiliação
  • Lindberg OR; Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, CA, USA.
  • McKinney A; Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, CA, USA.
  • Engler JR; Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, CA, USA.
  • Koshkakaryan G; Touro University California, College of Osteopathic Medicine, Vallejo, CA, USA.
  • Gong H; Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, CA, USA.
  • Robinson AE; Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, CA, USA.
  • Ewald AJ; Departments of Cell Biology, Oncology, and Biomedical Engineering, School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
  • Huillard E; Université Pierre et Marie Curie (UPMC) UMR-S975, Inserm U1127, CNRS UMR7225, Institut du Cerveau et de la Moelle Epiniere, Paris, France.
  • David James C; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
  • Molinaro AM; Department of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, CA, USA.
  • Shieh JT; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA.
  • Phillips JJ; Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Oncotarget ; 7(48): 79101-79116, 2016 Nov 29.
Article em En | MEDLINE | ID: mdl-27738329
ABSTRACT
Abnormal activation of the epidermal growth factor receptor (EGFR) due to a deletion of exons 2-7 of EGFR (EGFRvIII) is a common alteration in glioblastoma (GBM). While this alteration can drive gliomagenesis, tumors harboring EGFRvIII are heterogeneous. To investigate the role for EGFRvIII activation in tumor phenotype we used a neural progenitor cell-based murine model of GBM driven by EGFR signaling and generated tumor progenitor cells with high and low EGFRvIII activation, pEGFRHi and pEGFRLo. In vivo, ex vivo, and in vitro studies suggested a direct association between EGFRvIII activity and increased tumor cell proliferation, decreased tumor cell adhesion to the extracellular matrix, and altered progenitor cell phenotype. Time-lapse confocal imaging of tumor cells in brain slice cultures demonstrated blood vessel co-option by tumor cells and highlighted differences in invasive pattern. Inhibition of EGFR signaling in pEGFRHi promoted cell differentiation and increased cell-matrix adhesion. Conversely, increased EGFRvIII activation in pEGFRLo reduced cell-matrix adhesion. Our study using a murine model for GBM driven by a single genetic driver, suggests differences in EGFR activation contribute to tumor heterogeneity and aggressiveness.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Deleção de Sequência / Glioblastoma / Receptores ErbB Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Deleção de Sequência / Glioblastoma / Receptores ErbB Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article